semaglutide covered by medi cal Ozempic, Wegovy Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs medi cal semaglutide Semaglutide Prescription

It was first developed to help with type 2 diabetes, but strong results for obesity and weight loss have made it popular for other uses too

In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with OZEMPIC 0.5 mg and 1 mg, respectively

Psychological conditions Increased sweating and night sweats are a common side effect of stress and psychological conditions such as anxiety and depression

Additionally, social and privacy concerns about visible injection supplies or administration in shared spaces deter some individuals from pursuing otherwise appropriate treatment

Thirst is a lagging indicator of dehydration, and on GLP-1 medications, your thirst signals may be further blunted by the appetite-suppressing effects of the drug